Welcome to our dedicated page for Sight Sciences SEC filings (Ticker: SGHT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences, Inc. filing a Form 144 reports a proposed sale of 591 common shares with an aggregate market value of $1,992.32. The seller acquired these shares on 09/30/2025 through restricted stock vesting and the payment type is listed as compensation. The proposed approximate sale date is 10/06/2025 on NASDAQ. The filing shows 52,367,359 shares outstanding for the issuer and indicates no sales by the seller in the past three months. The filer attests there is no undisclosed material adverse information and includes the standard signature and legal notice language.
Sight Sciences (SGHT) disclosed an insider transaction by its Chief Financial Officer. On 10/02/2025, the officer reported a sale of 19,948 shares of common stock at $3.3 per share, coded “S.” Following the transaction, the officer directly holds 597,520 shares.
The filing notes the shares were sold to cover the reporting person’s tax liability associated with the vesting of restricted stock units. This reflects a routine tax-related disposition rather than a discretionary portfolio trade.
Sight Sciences (SGHT) President & CEO, Director, and 10% owner Paul Badawi reported a sale of common stock on 10/01/2025. He sold 24,441 shares at $3.34 per share (Code S), as noted in the filing’s footnote, to cover tax liabilities arising from the vesting of restricted stock units.
Following this transaction, Badawi beneficially owns 5,962,502 shares of Sight Sciences common stock directly. The filing indicates the disposition was related to tax withholding tied to equity compensation vesting.
David Badawi, Chief Technology Officer and director of Sight Sciences, Inc. (SGHT), reported a sale of 6,033 shares of common stock on 10/03/2025 at a price of $3.27 per share. The filing states the shares were sold to cover the reporting person's tax liability from the vesting of restricted stock units. After the sale, Mr. Badawi beneficially owned 1,864,992 shares of common stock.
This Form 144 for Sight Sciences, Inc. (SGHT) notifies a proposed sale of 9,731 common shares held at Fidelity Brokerage Services LLC with an aggregate market value of $31,848.59, with an approximate sale date of 10/03/2025. The shares were acquired on 09/30/2025 through restricted stock vesting and the acquisition payment is listed as compensation. The filing also discloses a prior sale by Jeremy Hayden of 9,160 common shares on 07/03/2025 for gross proceeds of $38,235.67. The filer represents, by signing, that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 filing: A shareholder filed a notice to sell up to 15,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 10/03/2025. The filing lists an aggregate market value of $49,276.20 for the proposed sale.
The shares were acquired via restricted stock vesting: 11,236 shares on 10/17/2024 and 3,764 shares on 10/18/2024, recorded as compensation. Shares outstanding were 52,367,359 at the time cited.
Recent activity over the past three months shows sales by Matthew Link of common stock: 10,000 shares for $35,227.21 on 09/12/2025; 15,990 shares for $55,291.81 on 09/16/2025; 20,000 shares for $73,400.00 on 09/19/2025; and 20,753 shares for $73,350.73 on 09/23/2025.
Sight Sciences, Inc. (SGHT) Form 144 summary: The filing notifies a proposed sale of 19,948 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $65,750.60. The sale is scheduled for 10/02/2025 on NASDAQ and the issuer reports 52,367,359 shares outstanding. The shares were acquired on 09/30/2025 through restricted stock vesting and were recorded as compensation. The filer also disclosed a prior sale of 19,260 shares on 07/02/2025 that generated $78,933.26 in gross proceeds. The notice includes the standard signature representation that the seller is unaware of undisclosed material adverse information.
Sight Sciences, Inc. (SGHT) Form 144 filing reports a proposed sale of 24,441 common shares through Fidelity Brokerage Services LLC on Nasdaq. The shares were acquired by restricted stock vesting on 09/30/2025 and are identified as compensation. The filer reports 52,367,359 shares outstanding for the class, and records an approximate aggregate market value of $81,740.48 for the shares to be sold with an approximate sale date of 10/01/2025. The filing also discloses that Paul Badawi sold 23,637 common shares on 07/01/2025 for gross proceeds of $98,133.73. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Sight Sciences entered a third amendment to its senior secured term loan with Hercules Capital, which allows borrowing of up to $65.0 million in total. The amendment adds another six months to the interest-only period, which now runs until February 1, 2027, giving the company more time before it must start repaying principal.
The change also reallocates an undrawn and unavailable $10.0 million tranche so that the amount the company can draw during the interest-only period increases from $15.0 million to $25.0 million, in minimum increments of $5.0 million, subject to approval by Hercules’ investment committee. In return for these changes, Sight Sciences paid Hercules a $50,000 fee plus certain costs and expenses.
Sight Sciences (SGHT) Form 144 shows a proposed sale of 20,753 common shares through Fidelity Brokerage Services, with an aggregate market value of $73,350.73 and an approximate sale date of 09/23/2025. The filer reports acquiring 5,753 shares on 10/16/2024 and 15,000 shares on 10/17/2024 via restricted stock vesting as compensation. The filing also discloses prior sales by the same person, Matthew Link: 4,889 shares on 07/02/2025 (gross proceeds $20,036.59), and three September 2025 sales totaling 60, - 10,000 shares (9/12/2025), 15,990 shares (9/16/2025), and 20,000 shares (9/19/2025) with reported gross proceeds shown in the filing.